Black Diamond Therapeutics, Inc. (BDTX) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

30/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

20

Strong Down

Sentiment

56

Mixed

Risk resilience

11

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Mark A. Velleca
Listed since: Jan 31, 2020
Employees: 21

Market position

Day range

Current $2.21

$2.15$2.26

52-week range

Current $2.21

$1.60$4.94

Open: $2.15
Previous close: $2.15
Volume: 656.73K; 0.46× average
Average volume: 1.41M; Average daily volume
Market cap: 126.64M USD
Beta: 3.29; Market reference 1
50-day average: $1.8572; +19.00% above average
200-day average: $2.4972; -11.50% below average

Financials

Financial statements

Income trends

Operating income

19.87M USD+98.65M USD

Net income

22.37M USD+92.04M USD

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	70M USD	—	—	—	—
Cost of goods sold	325K USD	—	437K USD	—	—
Gross profit	69.68M USD	—	−437K USD	—	—
Research and development	33.56M USD	51.31M USD	58.91M USD	64.44M USD	96.83M USD
Selling, general, and administrative	16.57M USD	27.47M USD	27.11M USD	28.39M USD	30.04M USD
Operating expenses	49.81M USD	78.78M USD	86.02M USD	92.83M USD	126.87M USD
Interest income	4.06M USD	2.18M USD	1.92M USD	2.03M USD	3.46M USD
Depreciation and amortization	325K USD	343K USD	437K USD	508K USD	205K USD
Operating income	19.87M USD	−78.78M USD	−86.46M USD	−92.83M USD	−126.87M USD
Net income	22.37M USD	−69.68M USD	−82.44M USD	−91.17M USD	−125.6M USD